Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

In the interconnected ASX healthcare sector it can be common for leaders to be involved in multiple companies and ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

The UK biotech sector raised £3.5 billion in equity financing last year amid challenges, according to a BIA report.